Free Trial

Research Analysts Set Expectations for Immunome Q1 Earnings

Immunome logo with Medical background
Remove Ads

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Lifesci Capital issued their Q1 2025 earnings estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will earn ($0.61) per share for the quarter. Lifesci Capital has a "Outperform" rating and a $20.00 price objective on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

A number of other research analysts have also issued reports on IMNM. Wedbush reiterated an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Monday. Piper Sandler cut their price objective on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $27.17.

View Our Latest Stock Report on Immunome

Immunome Price Performance

Shares of NASDAQ IMNM traded down $0.16 during midday trading on Thursday, hitting $8.77. 453,030 shares of the company's stock were exchanged, compared to its average volume of 896,133. Immunome has a twelve month low of $8.39 and a twelve month high of $26.70. The firm has a market cap of $699.64 million, a P/E ratio of -1.08 and a beta of 1.93. The stock's 50 day moving average price is $9.98 and its 200-day moving average price is $11.80.

Remove Ads

Insider Buying and Selling at Immunome

In other news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock worth $359,000 after purchasing an additional 1,520 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Immunome by 11.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company's stock valued at $202,000 after buying an additional 2,000 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Immunome by 26.5% in the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company's stock valued at $201,000 after buying an additional 3,974 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock valued at $1,546,000 after acquiring an additional 4,874 shares during the last quarter. Finally, Cerity Partners LLC boosted its stake in shares of Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company's stock worth $776,000 after acquiring an additional 5,043 shares in the last quarter. Institutional investors own 44.58% of the company's stock.

About Immunome

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Featured Stories

Earnings History and Estimates for Immunome (NASDAQ:IMNM)

Should You Invest $1,000 in Immunome Right Now?

Before you consider Immunome, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.

While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads